Statements (62)
| Predicate | Object |
|---|---|
| gptkbp:instance_of |
gptkb:Company
|
| gptkbp:bfsLayer |
3
|
| gptkbp:bfsParent |
gptkb:Takeda_Pharmaceutical_Company
gptkb:Glaxo_Smith_Kline |
| gptkbp:acquisition |
Acquired by a larger pharmaceutical company
|
| gptkbp:business_model |
research and development
operates in the US |
| gptkbp:ceo |
gptkb:Dr._J._Michael_Bishop
|
| gptkbp:clinical_trial |
Phase 1
Phase 2 Phase 3 targeted therapy various drug candidates in development ongoing clinical studies Phase 1 and Phase 2 trials |
| gptkbp:collaborations |
academic research institutions
Biopharmaceutical companies works with scientists globally |
| gptkbp:community_engagement |
engages with local communities
|
| gptkbp:developed_by |
innovative drug candidates
|
| gptkbp:economic_activity |
aims for sustainable growth
|
| gptkbp:financial_products |
private equity funding
|
| gptkbp:focus |
gptkb:healthcare_organization
cancer therapeutics |
| gptkbp:founded |
gptkb:2007
|
| gptkbp:founder |
gptkb:Dr._J._Michael_Bishop
|
| gptkbp:has_specialty |
has clinical expertise in oncology.
|
| gptkbp:headquarters |
gptkb:Malvern,_Pennsylvania
|
| gptkbp:healthcare |
improves patient access to therapies
|
| https://www.w3.org/2000/01/rdf-schema#label |
Tetra Logic Pharmaceuticals
|
| gptkbp:industry |
gptkb:Company
|
| gptkbp:innovation |
driven by innovation in drug development
pioneers therapeutic innovations |
| gptkbp:invention |
multiple patents filed
|
| gptkbp:investment |
Venture capital firms
oncology market engagement with investors |
| gptkbp:key_people |
gptkb:Dr._J._Michael_Bishop
gptkb:David_A._Dyer gptkb:Robert_J._Mc_Culloch |
| gptkbp:language_of_instruction |
multiple drug candidates
|
| gptkbp:market |
conducts market research
global pharmaceutical market |
| gptkbp:marketing_strategy |
strategic partnerships
focused on niche markets |
| gptkbp:outcome |
aims to improve patient outcomes
|
| gptkbp:parent_company |
gptkb:organization
|
| gptkbp:partnership |
Various academic institutions
collaborates with hospitals |
| gptkbp:products |
cancer drugs
T L32711 |
| gptkbp:publishes |
peer-reviewed journals
|
| gptkbp:regulatory_compliance |
FDA approval process
complies with FDA regulations |
| gptkbp:research_areas |
oncology
small molecule drugs |
| gptkbp:research_interest |
significant R& D investment
|
| gptkbp:safety_record |
focuses on drug safety
|
| gptkbp:team |
experienced leadership team
|
| gptkbp:technology |
proprietary drug delivery systems
|
| gptkbp:type |
gptkb:Company
|
| gptkbp:website |
www.tetralogic.com
|